Literature DB >> 18628403

New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug).

Vindhya Nawaratne1, Katie Leach, Nur Suratman, Richard E Loiacono, Christian C Felder, Blaine N Armbruster, Bryan L Roth, Patrick M Sexton, Arthur Christopoulos.   

Abstract

The M4 muscarinic acetylcholine (ACh) receptor (mAChR) is a potential therapeutic target but characterized by a lack of subtype-selective ligands. We recently generated "designer receptors exclusively activated by a designer drug" (DREADDs), which contained mutations of two conserved orthosteric-site residues (Y113C/A203G in the M4 mAChR) that caused a loss of ACh activity but a gain in responsiveness to clozapine-N-oxide (CNO). The current study characterized the interactions of the wild type and the M4 DREADD with a range of agonists, antagonists, and the recently discovered M4 mAChR allosteric potentiator, 3-amino-5-chloro-6-methoxy-4-methyl-thieno[2,3-b]pyridine-2-carboxylic acid cyclopropylamide (LY2033298). LY2033298 displayed positive binding cooperativity with ACh, neutral cooperativity with the antagonist, [3H]quinuclidinyl benzilate, and agonism for activation of phosphorylated extracellular signal-regulated kinase (ERK) 1/2 at the wild-type M4 mAChR. LY2033298's cooperativity with clozapine or CNO was weakly positive with respect to binding but profoundly negative with respect to LY2033298 signaling. Although the DREADD mutations increased the binding and function of clozapine-like compounds, all other agonists lost the ability to activate the mutant; for the orthosteric agonists ACh and pilocarpine, this was due partly to a reduced affinity, whereas the affinity of LY2033298 or the atypical agonist 4-I-[3-chlorophenyl]carbamoyloxy)-2-butynyltrimethylammnonium chloride was unaltered. The interaction between LY2033298 and clozapine-like compounds reverted to neutral cooperativity on the DREADD, whereas LY2033298 caused a striking functional rescue of ACh potency and efficacy at the DREADD. These results provide conclusive evidence for the retention of a functional allosteric site on the M4 DREADD and highlight a role for residues Tyr113 and Ala203 in the transmission of cooperativity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628403     DOI: 10.1124/mol.108.049353

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  49 in total

1.  A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation.

Authors:  Meritxell Canals; J Robert Lane; Adriel Wen; Peter J Scammells; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2011-11-15       Impact factor: 5.157

2.  Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms.

Authors:  Vindhya Nawaratne; Katie Leach; Christian C Felder; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2010-04-20       Impact factor: 5.157

3.  Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor.

Authors:  S Suratman; K Leach; Pm Sexton; Cc Felder; Re Loiacono; A Christopoulos
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

4.  DREADDnoughts Join in the Battle for Seizure Control.

Authors:  Matthew J Korn; Jack M Parent
Journal:  Epilepsy Curr       Date:  2015 Mar-Apr       Impact factor: 7.500

5.  Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias.

Authors:  Karen J Gregory; Nathan E Hall; Andrew B Tobin; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2010-01-05       Impact factor: 5.157

Review 6.  Remote control of neuronal signaling.

Authors:  Sarah C Rogan; Bryan L Roth
Journal:  Pharmacol Rev       Date:  2011-03-17       Impact factor: 25.468

7.  5-HT stimulation of heart rate in Drosophila does not act through cAMP as revealed by pharmacogenetics.

Authors:  Zana R Majeed; Charles D Nichols; Robin L Cooper
Journal:  J Appl Physiol (1985)       Date:  2013-10-03

8.  Crystal structures of the M1 and M4 muscarinic acetylcholine receptors.

Authors:  David M Thal; Bingfa Sun; Dan Feng; Vindhya Nawaratne; Katie Leach; Christian C Felder; Mark G Bures; David A Evans; William I Weis; Priti Bachhawat; Tong Sun Kobilka; Patrick M Sexton; Brian K Kobilka; Arthur Christopoulos
Journal:  Nature       Date:  2016-03-09       Impact factor: 49.962

9.  Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors.

Authors:  Georgia M Alexander; Sarah C Rogan; Atheir I Abbas; Blaine N Armbruster; Ying Pei; John A Allen; Randal J Nonneman; John Hartmann; Sheryl S Moy; Miguel A Nicolelis; James O McNamara; Bryan L Roth
Journal:  Neuron       Date:  2009-07-16       Impact factor: 17.173

Review 10.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.